Clinical Trial Update: A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer [Phase 2]

View source ↗

Summary

Phase II window-of-opportunity trial evaluating PRMT5 inhibitor GSK3326595 in early-stage breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GSK3326595

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED